Drug intelligence / Profile preview

bevacizumab + pyrotinib

Development stage: Unknown
Lead developer: Genentech
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Intravenous, Oral

Overview

Bevacizumab + pyrotinib is a combination therapy being investigated primarily for HER2-positive breast cancer with brain metastases. Bevacizumab is an anti-angiogenic agent that targets vascular endothelial growth factor (VEGF), while pyrotinib is a tyrosine kinase inhibitor that targets HER2. This combination is thought to have synergistic effects in treating brain metastases by enhancing drug penetration through the blood-brain barrier and providing dual targeting of tumor growth pathways.

Targets

EGFR (Epidermal growth factor receptor)VEGFA (Vascular endothelial growth factor A)ERBB2 (Erb-b2 receptor tyrosine kinase 2)ERBB4 (Erb-b2 receptor tyrosine kinase 4)

Beyond the preview

Go deeper on bevacizumab + pyrotinib.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on bevacizumab + pyrotinib.

Explore the full profile